Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium + Lactobacillus rhamnosus is a combination of probiotic bacteria investigated for its potential health benefits, particularly in the management of skin conditions like atopic dermatitis (eczema) and infantile eczema. [4, 5] Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host. [4] This specific combination is believed to work by modulating the gut microbiome, which in turn influences the host's immune system to reduce inflammatory responses. [3, 6] Clinical studies have shown that this combination may improve the severity of atopic dermatitis, particularly in food-sensitized children. A meta-analysis also suggests that a mixed strain of Lactobacillus and Bifidobacterium can effectively reduce the incidence of eczema in infants under three years old. [12] However, the effectiveness can be strain-specific, and some studies show that Lactobacillus rhamnosus may be more effective than certain Bifidobacterium strains for eczema prevention. [7, 8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bifidobacterium + lactobacillus rhamnosus.